Comparative Pharmacology
Head-to-head clinical analysis: LAMIVUDINE ZIDOVUDINE ABACAVIR versus LAMIVUDINE ZIDOVUDINE TABS 150MG 300MG CO PACKAGED WITH NEVIRAPINE TABS 200MG.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LAMIVUDINE ZIDOVUDINE ABACAVIR versus LAMIVUDINE ZIDOVUDINE TABS 150MG 300MG CO PACKAGED WITH NEVIRAPINE TABS 200MG.
LAMIVUDINE; ZIDOVUDINE; ABACAVIR vs LAMIVUDINE, ZIDOVUDINE TABS 150MG/300MG CO-PACKAGED WITH NEVIRAPINE TABS 200MG
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lamivudine, zidovudine, and abacavir are nucleoside reverse transcriptase inhibitors (NRTIs). They are phosphorylated intracellularly to active metabolites that compete with natural nucleotides for incorporation into viral DNA, causing chain termination and inhibition of HIV reverse transcriptase.
Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) that inhibits HIV reverse transcriptase via DNA chain termination after intracellular phosphorylation to lamivudine triphosphate. Zidovudine is also an NRTI that inhibits HIV reverse transcriptase after phosphorylation to zidovudine triphosphate. Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds directly to reverse transcriptase, causing enzyme inhibition.
One tablet (300 mg abacavir, 150 mg lamivudine, 300 mg zidovudine) orally twice daily.
One tablet of lamivudine/zidovudine (150 mg/300 mg) orally twice daily. One tablet of nevirapine (200 mg) orally once daily for 14 days, then one tablet twice daily thereafter.
None Documented
None Documented
Lamivudine: 5-7 hours (single dose), prolonged to ~11 hours in renal impairment; Zidovudine: 1.1 hours (terminal), increased to 1.4 hours in hepatic impairment; Abacavir: 1.5 hours (terminal), slightly prolonged in hepatic impairment; Clinical context: Dosing interval of 12 hours requires therapeutic drug monitoring in renal/hepatic dysfunction.
Lamivudine: 5-7 hours (terminal half-life); prolonged to ~10-15 hours in advanced HIV infection; increased with renal impairment. Zidovudine: 0.5-3 hours (mean ~1 hour); prolonged to ~1.5-3 hours in renal impairment; intracellular active metabolite zidovudine-triphosphate has half-life ~3-7 hours. Nevirapine: ~25-30 hours (single dose), ~40-60 hours with multiple dosing (autoinduction reduces to ~20-30 hours after 2-4 weeks).
Lamivudine: ~70% excreted unchanged in urine via glomerular filtration and active tubular secretion; Zidovudine: ~75% excreted as metabolites (primarily 5'-glucuronide) in urine, with <20% unchanged; Abacavir: ~83% excreted as metabolites in urine (via alcohol dehydrogenase and glucuronidation) and ~16% in feces; Total renal elimination accounts for >80% of clearance for all three components.
Lamivudine: ~70% renal (glomerular filtration and active tubular secretion) as unchanged drug; ~30% metabolized to inactive metabolites (trans-sulfoxide) excreted renally. Zidovudine: ~75% renal (metabolite zidovudine-glucuronide) and ~20% unchanged; ~5% fecal. Nevirapine: ~80% renal (metabolites, mainly 2-hydroxy- and 3-hydroxy-nevirapine glucuronides), ~10% fecal, <5% unchanged.
Category A/B
Category A/B
NRTI
NRTI